Market Closed -
OTC Markets
09:28:04 16/05/2023 pm IST
5-day change
1st Jan Change
16.97
USD
-.--%
-.--%
-.--%
Sales 2024
26.45B
170M
14.22B
Sales 2025 *
30.5B
196M
16.4B
Capitalization
58.49B
376M
31.45B
Net income 2024
5.53B
35.58M
2.97B
Net income 2025 *
4.3B
27.66M
2.31B
EV / Sales 2024
2.39
x
Net Debt
2024
*
19.51B
125M
10.49B
Net Debt
2025
*
22.77B
146M
12.24B
EV / Sales 2025 *
2.66
x P/E ratio 2024
11.4
x
P/E ratio 2025 *
13.6
x
Employees
1,341
Yield 2024
3.29%
Yield 2025 *
3.56%
Free-Float
48.8%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Shin Nippon Biomedical Laboratories, Ltd. Announces Fiscal Year End Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 25, 2024; Provides Second Quarter End and Fiscal Year End Dividend Guidance for the Fiscal Year Ended March 31, 2025
08/05
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025
08/05
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
02/02
CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval
18/01
MT
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024
07/11
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
02/23/02
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
02/23/02
CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting
15/23/15
CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.
08/23/08
CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen
29/23/29
MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023
08/23/08
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
08/23/08
CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen
18/23/18
MT
More news
Managers
Title Age Since
Chief Executive Officer
65
01/81/01
Director of Finance/CFO
55
01/02/01
Compliance Officer
-
01/84/01
Members of the board
Title Age Since
Chief Executive Officer
65
01/81/01
Director/Board Member
38
01/17/01
Sales & Marketing
64
01/02/01
More insiders
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
More about the company
Last Close Price
1,405
JPY
Average target price
2,800
JPY
Spread / Average Target
+99.29%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1